NSABP B-49: A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Aims: The purpose of this study is to compare the effectiveness of three different combinations of chemotherapy drugs: 1) docetaxel and cyclophosphamide; 2) doxorubicin, cyclophosphamide and docetaxel; and 3) doxorubicin, cyclophosphamide and paclitaxel. All of these drugs are used in standard combinations of chemotherapy for breast cancer.  The researchers also want to learn about the side effects of the combinations of drugs used in this study to see if there are any differences between the two-drug and three-drug chemotherapy combinations.
Diagnosis: Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH12-341
Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes 

Novartis BKM120: A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 with Fulvestrant, in Postmenopausal Women with Hormone Receptor-Positive HER2-Negative Locally Avanced or Metastatic Breast Cancer which Progressed On or After Aromatase Inhibitor Treatment
Aims: Information from the optional tumor biopsy samples will be used to study wheter disease status and/or effect of treatment with BKM120 can be detected with biomarkers. BKM120 blocks the activity of a protein called PI3K. Many tumors are known to have an activated PI3K pathway. PI3K pathway activation depends on changes of multiple molecules, in particular, the changes of PIK2CA (a gene coding for the PI3K protein) or a molecule called PTEN.
Diagnosis: Metastatic Breast Cancer
Principal Investigator: Douglas Merkel, MD 
IRB Approval Number: EH12-345
Sponsor: Norvartis
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

LATTE: Long Term Anastrozole versus Tamoxifen Treatment Effects
Aims: The LATTE study is an extension study to the now closed ATAC trial that took place 10 years ago. LATTE aims to collect long term follow-up information since the conclusion of the ATAC study and for at least another 5 years.
Diagnosis: Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH13-352
Sponsor: American Cancer Society, Inc/ Queen Mary University of London
Contact: Interested patients should contact research coordinator Nancy Haefling at 847.503.1188
Open to Enrollment: Yes 

× Alternate Text